- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01140815
Functional Performance of the Journey Deuce Bicompartmental Versus the Genesis II Total Knee System (Deuce)
July 10, 2014 updated by: Nancy Parks, Anderson Orthopaedic Research Institute
A Prospective, Single-Center, Randomized Study Comparing the Functional Performance of the Journey Deuce Bicompartmental With the Genesis II Total Knee System
The objectives of this study are to assess the safety and effectiveness of the Journey Deuce Bicompartmental Knee System at 4-6 weeks, 4 months, 1 year, and 2 years when compared to total knee replacement using the Genesis II Total Knee System.
The hypothesis is that the Journey Deuce Bicompartmental Knee System is as safe and effective as the Genesis II Total Knee System at the 2-year.
The null hypothesis is that there is no difference between the groups.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
50
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Virginia
-
Alexandria, Virginia, United States, 22307
- Anderson Orthopaedic Research Institute
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
30 years to 65 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patient presents with non-inflammatory degenerative joint disease of the medial and patellofemoral compartments requiring a unilateral knee replacement.
- Patient is 30 to 65 years of age, inclusive.
- Patient is willing to consent to participate in the study by signing and dating an IRB-approved consent form.
- Patient plans to be available for follow-up through 2 years postoperative.
Exclusion Criteria:
- Patient is known to have insufficient femoral or tibial bone stock resulting from conditions such as cancer, distal femoral/proximal tibial osteotomy, significant osteoporosis or metabolic bone disorders.
- Patient is immunosuppressed, has an autoimmune disorder, or an immunosuppressive disorder (i.e. chronic condition characterized by markedly inhibited ability to respond to antigenic stimuli.) Examples of such conditions include patients who are on immunosuppressive therapy (corticosteroid hormones in large amounts, cytotoxic drugs, antilymphocytic serum or irradiation in large doses) or patients with acquired immunodeficiency syndrome (AIDS).
- Patient has inflammatory arthritis (e.g. rheumatoid arthritis)
- Patient has BMI > 35.
- Patient has had major knee surgery in the past i.e. HTO, unicondylar knee replacement, failed fracture fixation.
- Patient has an active infection, local or systemic.
- Patient has physical, emotional or neurological conditions that would compromise the patient's compliance with postoperative rehabilitation and follow-up (e.g.: drug or alcohol abuse, serious mental illness, or general neurological conditions such as Parkinson, Multiple sclerosis, etc.).
- Patient has ACL deficiency in the study knee.
- Patient has hip arthritis and/or replacement.
- Patient has lateral compartment disease.
- Patient is pregnant or plans to become pregnant during the course of the study.
- Patient is on workman's compensation.
- Patient has a known sensitivity to materials in the device.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
ACTIVE_COMPARATOR: Total
The Smith and Nephew Total Knee System
|
Smith and Nephew Total Knee Replacement
|
|
EXPERIMENTAL: Deuce
The Journey Deuce Bicompartmental Knee System
|
Smith and Nephew Bicompartmental Knee Replacement
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
2-Year Knee Society Score
Time Frame: 2 years
|
Knee Society Clinical Rating System (KSS) provides for separate knee pain and patient functional assessment scores.
Scale of 0-100 with higher values representing a better score.
|
2 years
|
|
6-Week Knee Society Score
Time Frame: 6 weeks
|
Knee Society Clinical Rating System (KSS) provides for separate knee pain and patient functional assessment scores.
Scale of 0-100 with higher values representing a better score.
|
6 weeks
|
|
4-Month Knee Society Score
Time Frame: 4 months
|
Knee Society Clinical Rating System (KSS) provides for separate knee pain and patient functional assessment scores.
Scale of 0-100 with higher values representing a better score.
|
4 months
|
|
1-year Knee Society Score
Time Frame: 1 year
|
Knee Society Clinical Rating System (KSS) provides for separate knee pain and patient functional assessment scores.
Scale of 0-100 with higher values representing a better score.
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
6-Week X-rays
Time Frame: 6 weeks
|
Knee Society Roentgenographic Evaluation and Scoring System will assess alignment; any evidence of loosening as indicated primarily by radiolucencies > 2mm; evidence of surface wear or particulate debris generation as indicated by early osteolysis, implant migration, or other clinical or radiographic abnormalities.
Number of participants with these radiographic abnormalities by X-ray at 6 weeks are reported.
|
6 weeks
|
|
4-month X-rays
Time Frame: 4 months
|
Knee Society Roentgenographic Evaluation and Scoring System will assess alignment; any evidence of loosening as indicated primarily by radiolucencies > 2mm; evidence of surface wear or particulate debris generation as indicated by early osteolysis, implant migration, or other clinical or radiographic abnormalities.
Number of participants with these radiographic abnormalities by X-ray at 4 months are reported.
|
4 months
|
|
1-year X-rays
Time Frame: 1 year
|
Knee Society Roentgenographic Evaluation and Scoring System will assess alignment; any evidence of loosening as indicated primarily by radiolucencies > 2mm; evidence of surface wear or particulate debris generation as indicated by early osteolysis, implant migration, or other clinical or radiographic abnormalities.
Number of participants with these radiographic abnormalities by X-ray at 1 year are reported.
|
1 year
|
|
2-year X-rays
Time Frame: 2 years
|
Knee Society Roentgenographic Evaluation and Scoring System will assess alignment; any evidence of loosening as indicated primarily by radiolucencies > 2mm; evidence of surface wear or particulate debris generation as indicated by early osteolysis, implant migration, or other clinical or radiographic abnormalities.
Number of participants with these radiographic abnormalities by X-ray at 2 years are reported.
|
2 years
|
|
2-year Patient Surveys
Time Frame: 2 years
|
Serial patient evaluation of function will be assessed using the Oxford Knee Outcome Questionnaire.
The Oxford Questionnaire consists of 12 questions, each with a value of 0 (bad) to 4(good).
The results are summed for a total score of 0(bad) to 48(good).
|
2 years
|
|
6-week Functional Testing
Time Frame: 6 weeks
|
A timed Functional Assessment Test, gait analysis, and balance testing for lower extremity motor function will be performed.
Fewer seconds in the result indicates faster performance, which is a positive result.
|
6 weeks
|
|
4-month Functional Testing
Time Frame: 4 months
|
A timed Functional Assessment Test, gait analysis, and balance testing for lower extremity motor function will be performed.
Fewer seconds in the result indicates faster performance, which is a positive result.
|
4 months
|
|
1-year Functional Testing
Time Frame: 1 year
|
A timed Functional Assessment Test, gait analysis, and balance testing for lower extremity motor function will be performed.
Fewer seconds in the result indicates faster performance, which is a positive result.
|
1 year
|
|
2-year Functional Testing
Time Frame: 2 years
|
A timed Functional Assessment Test, gait analysis, and balance testing for lower extremity motor function will be performed.
Fewer seconds in the result indicates faster performance, which is a positive result.
|
2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Gerard A. Engh, MD, AORI
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2007
Primary Completion (ACTUAL)
May 1, 2013
Study Completion (ACTUAL)
May 1, 2013
Study Registration Dates
First Submitted
May 28, 2010
First Submitted That Met QC Criteria
June 8, 2010
First Posted (ESTIMATE)
June 10, 2010
Study Record Updates
Last Update Posted (ESTIMATE)
August 4, 2014
Last Update Submitted That Met QC Criteria
July 10, 2014
Last Verified
July 1, 2014
More Information
Terms related to this study
Other Study ID Numbers
- AORI2010-0103
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.